Flow Cytometry is a laboratory method that helps measure the percentage of live cells and the number of cells & their characteristics of cells like shape & size, using a sample of bone marrow, blood, or any other tissue. Cells are stained with a light-sensitive dye, suspended in a fluid, and then passed through a beam of light, to which the stained cells react and generate the results. This process is used in research and helps diagnose certain diseases, including cancer.
The Global Flow Cytometry in Oncology Market is anticipated to grow at a CAGR of around 11.2% during the forecast period, i.e., 2021-26. Flow cytometry has evolved for a long time from a niche laboratory technique to a routine method used by immunologists & pathologists for diagnosing & monitoring patients with cancer.
|Study Period||Historical Data: 2016-19|
|Base Year: 2020|
|Forecast Period: 2021-26|
|Regions Covered||North America: USA, Canada, Mexico|
|Europe: Germany, UK, France, Italy, Spain, Others|
|Asia-Pacific: China, India, Japan, South Korea|
|South America: Brazil, and Others|
|Middle East & Africa: UAE, Saudi Arabia, South Africa|
|Key Companies Profiled||Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytognos, S.L., Danaher Corporation, Luminex Corporation, Sony Corporation, Cytek Biosciences|
|Unit Denominations||USD Million/Billion|
The growth of the global flow cytometry in oncology market is likely to be driven primarily by the mounting prevalence of hematological malignancies and rising consumer awareness about precision medicine & tailored therapies. Nearly every 3 minutes, one person in the US gets diagnosed with lymphoma, leukemia, or myeloma. It is estimated that 186,400 people will be diagnosed with lymphoma, leukemia, or myeloma across the US in 2021.
Nevertheless, rapid developments in the field of cancer diagnostics and the burgeoning adoption of flow cytometers by end-users for therapeutic monitoring & conducting cancer diagnosis are other crucial factors projected to drive the global market during 2021-26.
Impact of Covid-19 on the Global Flow Cytometry in Oncology Market
The advent of Covid-19 in 2020 minimally impacted the Global Flow Cytometry in Oncology Market since the industry is entirely research-based. However, manufacturers in the global market witnessed revenue losses in the first two quarters of the fiscal year, 2020-21. Further, temporary halts on research activities associated with flow cytometry and the low influx of cancer patients in hospitals also led to a decline in the market growth.
However, healthcare systems are rapidly reorganizing cancer services to enhance their facilities and ensure that patients receive essential care continuously while minimizing exposure to Covid-19 infection. Hence, the coming years are set to generate remunerative opportunities for the Global Flow Cytometry in Oncology Market.
Based on Technology:
Of them all, Cell-Based flow cytometry accounted for more than 80% share of the Global Flow Cytometry in Oncology Market. This technology uses antibody-fluorophore conjugates to specify the number of antibodies present in the cells and also helps determine the absolute percentage of cells present in the sample.
The booming demand for Cell-Based flow cytometry is attributed majorly to its clinical applicability for the diagnosis & screening of hematological malignancies. Additionally, its application for Minimal Residual Testing (MRD) has become evident, indicating the presence of blast cells in patients suffering from leukemia, particularly for Acute Lymphoblastic Leukemia (ALL).
Through cell-based flow cytometry technology, researchers and physicians can directly quantify a specific target of interest in each cell, majorly based on the level of fluorescence emitted by that particular cell. Such advancements in flow cytometry are expected to propel its overall market growth in the coming years.
Based on Type:
Here, Breast Cancer acquired the largest market share in recent years, mainly due to the mounting focus on research for understanding the applicability of flow cytometry in breast cancer screening, increasing awareness about early breast cancer diagnosis, rising focus on therapeutic outcomes, and bolstering adoption of precision medicine in oncology.
Breast Cancer is the most common cancer among women worldwide, with a high mortality rate. According to the World Cancer Research Fund (WCRF), breast cancer represented 12.30% of the total cancer cases worldwide in 2018.
In addition, the application of flow cytometry in quantifying nuclear DNA content offers critical insights about ploidy status, percentage fraction of S-phase, and DNA index, which help physicians define high-risk breast cancer patients. Since early screening & detection play a critical role in improving the survival rate of patients with breast cancer, the utility of flow cytometry-based products is expected to increase significantly in the coming years.
Geographically, the Global Flow Cytometry in Oncology Market expands across:
Of all regions globally, North America dominated the Flow Cytometry in Oncology Market in the previous few years, and the same trend is likely through 2026. The region is home to several industry players currently updating their portfolios to present advanced products for cancer diagnostics & screening.
With the emergence of assays for disease detection and assessment of drug resistance, flow cytometry has become increasingly crucial to determining prognosis in cancer patients. Hence, with increasing cancer cases in the US, the demand for flow cytometry for determining prognosis is set to surge notably over the forecast years and contribute to the overall growth of the regional market.
Further, the surging instances of several hematological malignancies in the region are fueling the need for advanced flow cytometry-based cancer testing products. Additionally, the burgeoning adoption of next-generation flow cytometry products in the US for routine cancer testing is another crucial aspect significantly promoting the regional market growth.
Key Questions Answered in the Market Research Report:
Frequently Asked Questions
A. The Global Flow Cytometry in Oncology Market is expecting around 11.2% CAGR during 2021-26.
A. Cell-Based technology is expected to emerge as an area of remunerative opportunities for the leading players in the Global Flow Cytometry in Oncology Market through 2026.
A. Increasing incidents of hematological malignancies and growing consumer awareness for tailored therapies & precision medicine are the key growth opportunities projected to drive the Global Flow Cytometry in Oncology Market over the coming years.